Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Company Overview - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced treatment applications for cancers throughout the body [2] - The company utilizes proprietary technology with the alpha-emitting isotope 212Pb to deliver targeted radiation specifically to cancer cells via specialized targeting peptides [2] - Complementary imaging diagnostics are being developed that incorporate the same targeting peptides, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Development - The company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are currently in Phase 1/2a imaging and therapy trials for metastatic melanoma and neuroendocrine tumors at leading academic institutions [3] - A proprietary 212Pb generator has been developed to secure key isotopes for clinical trial and commercial operations [3] Upcoming Financial Reporting - The company will report its second quarter 2024 financial results and provide a business update on August 12, 2024, after market close [1]